News
ImmuneRegen News
ImmuneRegen Adds Respected Japanese Research Scientist to Scientific Advisory Board
Dr. Akihiro Shimosaka Joins Biotech Company
Scottsdale, Arizona -- January 26, 2004 -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBOE.OB - News) today announced that it has added Akihiro Shimosaka, PhD to its Scientific Advisory Board for its wholly owned subsidiary, ImmuneRegen BioSciences, Inc., and to work with its potential expansion into the Asian Pacific area, more specifically Singapore as the company is expecting to establish a research facility at the newly developed Biopolis in Singapore.
Dr. Shimosaka brings over 30 years of research and development experience and a wealth of knowledge to IR BioSciences' Scientific Advisory Board. He began his career in the late 1960s with Kirin Brewing as a research scientist. He continued his R&D career with Kirin for 25 years, during which he steered Kirin into a partnership with Amgen to further develop Kirin's R&D program. After joining forces with Amgen, Shimosaka worked on drugs for brain tumors and for drug resistant leukemia and discovered HGF (an oncology drug). He has been a key part of discovery research for a number of drugs/compounds throughout his career.
"Appointing Dr. Shimosaka to our Scientific Advisory Board formalizes our desire to move into the Asian Pacific region in regard to ImmuneRegen's research," states Michael K. Wilhelm, Chief Executive Officer of IR BioSciences Holdings, Inc. "His respected research background in biosciences and his wealth of contacts will undoubtedly help expand our relationships with other research scientists and government agencies in the region. We look forward to the financial and scientific opportunities his presence brings."
About Dr. Akihiro Shimosaka
Dr. Akihiro Shimosaka is currently the director in the Research & Development Division for the Research Foundation for Community Medicine in Japan. In addition to this position, he also holds an advisory position at EPS Co, honorary professorships at the Institute of Hematology in Peking Union Medical College at the Chinese Academy of Medical Sciences, at the Hematology Research Institute of Heilongjang, and at Xi'an Jiatong University, as well as visiting professorships at The Cancer Institute at The Fourth Medical University and the Department of Chemical Engineering at Dailan Nationality College, all located in China.
Shimosaka also belongs to several industry associations, including: the Japanese Society of Agricultural Chemistry, the Japanese Association for Cancer Research, the Japanese Society for Clinical Oncology, the Japan Chemical Society, the Japanese Society for Hematology, the Japanese Society for Regenerative Therapy, the International Society for Hematology, the International Society of Experimental Hematology, the European Hematology Association, the American Society for Hematology, the American Society for Clinical Oncology, the American Association for Cancer Research and the New York Academy of Sciences.
Additionally, Shimosaka holds a bachelor's and graduate degree from the University of Tokyo, where he also served as a research scientist in the Institute of Applied Microbiology.
About ImmuneRegen BioSciences, Inc.
a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com.
Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements.
Contact:
Amendola Communications for ImmuneRegen
Jan Shulman, 480-664-8412 ext. 12
jshulman@ACmarketingPR.com
or
Jodi Amendola, 480-664-8412 ext 11
jamendola@ACmarketingPR.com
###
Copyright © 2003-2008, ImmuneRegen Biosciences, Inc.
All rights reserved.